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Abstract
Background:  In 1998 a formal process using the criteria of safety, effectiveness and cost-
effectiveness (evidence based medicine) on the introduction and use of new medical procedures
was implemented in Australia. As part of this process an expert panel, the Medical Services
Advisory Committee (MSAC) was set up. This paper examines the effectiveness of this process
based on the original criteria, that is, evidence based medicine.
Method: The data for this analysis was sourced primarily from that made available in the public
domain. The MSAC web site provided Minutes from MSAC meetings; Annual Reports; Assessment
and Review reports; Progress status; and Archived material.
Results:  The total number of applications submitted to the MSAC has been relatively low
averaging approximately only fourteen per year. Additionally, the source of applications has quickly
shifted to the medical devices, equipment and diagnostic industry as being the major source of
applications. An overall average time for the processing of an application is eighteen months.
Negative recommendations were in most cases based on insufficient clinical evidence rather than
clinical evidence that clearly demonstrated a lack of clinical effectiveness. It was rare for a
recommendation, either positive or negative, to be based on cost-effectiveness.
Conclusion: New medical procedures are often the result of a process of experimentation rather
than formally conducted research. Affordability and the question of who should pay for the
generation, collection and analysis of the clinical evidence is perhaps the most difficult to answer.
This is especially the case where the new procedure is the result of a process of experimentation
with an old procedure. A cost-effective way needs to be found to collect accep levels of evidence
proving the clinical effectiveness of these new procedures, otherwise the formal processes of
evaluation such as that used by the Australian MSAC since 1998 will continue to run the risk of
committing Type II errors, that is, denying access to medical procedures that are beneficial and
efficient.
Introduction
Arising out of the uncertainty in decision making in any
health care sector decision makers are faced with the
dilemma of determining which has the greater risk, mak-
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ing available medical procedures that are ineffective or
even harmful (Type I error) or, denying access to medical
procedures that are beneficial and efficient (Type II error).
Owing to the long shadow of thalidomide, there may be
an over-emphasis by decision makers on the avoidance of
a Type I error. Additionally, the growing availability of
new technology and the resultant cost blow-outs may also
have biased decision makers against making a Type I
error. The combined effect may result in an unacceptable
level of denying access to medical procedures that are ben-
eficial and efficient (Type II errors). This potential
dilemma can be shown diagrammatically as in Table 1.
In April 1998 the then Federal Minister for Health and
Family Services announced that Australia had become the
first nation in the world to formally adopt evidence-based
medicine (EBM) as a key feature of its health system with
all new medical procedures being independently evalu-
ated by an expert panel before being admitted to the
Medicare Benefits Schedule.
"This new vetting procedure will make quality a central feature
of the health system by ensuring that only medical procedures
and new technologies which were safe, cost-effective and of real
benefit to patients were funded through Medicare. We will no
longer find ourselves in the untenable position of new proce-
dures being used in Australia simply on the basis of anecdotal
evidence or because of aggressive marketing. The introduction
of evidence based medicine and the committee means that the
gap between research knowledge and clinical practice will nar-
row, and patients will benefit earlier from the most advanced
procedures drawing on the best scientific and medical evi-
dence."[1]
In Australia, for a medical procedure to attract funding
covering the fee for the medical practitioner paid in the
case of privately insured patients (43% of the population
[2]), the procedure must have a Medicare Benefits Sched-
ule (MBS) Item Number. Although this Item Number
only directly determines the basic scheduled fee payable
to the medical practitioner, indirectly it determines the
payment of all other costs associated with the procedure
(theatre, bed-days, equipment and prosthesis) since these
payments are contingent on the procedure having this
MBS Item Number.
Evaluation of evidence accompanying applications from
the medical profession for the listing of new medical serv-
ices on the Australian Medicare Benefits Schedule (MBS)
is not new. The assessment of evidence has always been an
integral part of the listing process of medical technologies
and services on the MBS via a mix of specialist consulta-
tive and advisory bodies. The creation of the MSAC was
seen as a way of formalising and strengthening this proc-
ess, especially in terms of the cost-effectiveness criterion.
The guidelines for this new system of applications to the
Medical Services Advisory Committee (MSAC) were
loosely based on the Australian Guidelines for submis-
sions to the Pharmaceutical Benefits Advisory Committee
(PBAC) for the evaluation of all new pharmaceutical seek-
ing listing on the Australian Pharmaceutical Benefits
Schedule (PBS) that was made mandatory in Australia in
January 1993 [3]. A listing on this schedule results in the
pharmaceutical being subsidised by the Australian Gov-
ernment.
Although there are many similarities between the process
used for pharmaceuticals and the new process for medical
procedures, there are a number of important differences.
Submissions to the PBAC for PBS listing of a pharmaceu-
tical include the evaluation of all the evidence by the com-
pany making the submission (usually the manufacturer or
distributor). This evidence is reviewed by the Pharmaceu-
tical Benefits Branch (PBB) and the process is totally con-
fidential until the outcome of the submission is made
public (a one page summary referred to as the Public Sum-
mary Document). In contrast, applications to the MSAC
are evaluated by contractors employed by the Medicare
Benefits Branch (MBB). Additionally, this process has a
reasonably high level of transparency with publication on
a Web site of the receipt of the application, its progress,
and a detailed written report of the outcome.
Approximately one hundred submissions are received by
the Pharmaceutical Benefits Branch (PBB) each year. On
Table 1: Dilemma associated with Type I and Type II Errors
Procedure is Beneficial Procedure is Harmful
New procedure approved Correct Decision Type 1 Error: Allowing a harmful procedure. Victims 
are identifiable and traceable. Error is self-correcting
New procedure disapproved Type 2 Error: Disallowing a beneficial procedure. 
Victims are not identifiable. Error is not self-
correcting
Correct DecisionAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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average, approximately nineteen applications or refer-
ences are received by the Medicare Benefits Branch (MBB)
for the listing of procedures.
The safety and efficacy of a pharmaceutical must already
have been established by the Australian Therapeutic Good
Administration (TGA) leaving only the effectiveness and
cost-effectiveness to be established in the submission to
the PBAC. An application to the MSAC evaluates safety,
efficacy, effectiveness and cost-effectiveness of the proce-
dure all in the one evaluation.
The time between the lodgement of the submission and
the listing of the pharmaceutical on the PBS, assuming a
positive outcome, is nine months [4]. A period of twenty
four months between the lodgement of an application to
the MSAC and the listing of the procedure on the MBS is
considered to be standard.
Pharmaceuticals listed on the PBS are subsidised by the
Australian Government for the whole population regard-
less of private health insurance status. The listing of a pro-
cedure on the MBS result in subsidy only to those covered
by private health insurance, approximately 43% of the
population as at December 2004 [5].
The establishment of the Medical Services Advisory Com-
mittee (MSAC) by the Australian Federal Government had
three key objectives [1].
• Only medical procedures and new technologies which
were safe, cost-effective and of real benefit to patients
would be funded through Medicare.
￿ There would be a more rigorous assessment by the
MSAC to ensure that the medical procedure and new tech-
nology was safe, cost effective and of real benefit to the
patient.
￿ The gap between research knowledge and clinical prac-
tice would narrow, and patients would benefit earlier
from the most advanced procedures drawing on the best
scientific and medical evidence.
After more than six years of operation, it may now be
timely to review how effective the MSAC has been, both in
terms of screening the introduction of new procedures as
well as a possible hurdle to the introduction of new tech-
nology supplied by the medical devices and equipment
industry. This review of the achievement of the original
objective of the MSAC is based on:
1. Usage Rate of the MSAC process and source of applica-
tions
2. Time taken for processing MSAC applications and refer-
ences
3. Recommendations and outcomes of MSAC applica-
tions and references
Method
Data sources
The data for this analysis was sourced primarily from that
made available in the public domain. The MSAC wed site
provided minutes from MSAC meetings, annual reports,
assessment and review reports, progress status and
archived material.
In addition to this primary source, especially in the case
where contradiction arose, verbal clarification was sought
from various officers in the Health Technology Section
and the applicants of individual applications.
Calculation of duration of assessment
In Tables 2a and 2b, the calculation of the duration of
assessment for applications was the time between
acknowledgment of receipt of the application at a MSAC
meeting and the date of sign-off by the Minister for Health
and Ageing. Applications submitted before December
2004 that had not been signed off by the Minister have a
duration shown as a number of months with a plus sign
representing the duration between acknowledgment of
receipt at a meeting of the MSAC and December 2004.
These estimates are considered to be conservative since
the application could have been received up to three
months before being acknowledged at a meeting. For
example, Application 1042 was acknowledged at the May
MSAC meeting but was actually received 1st March 2001.
Results
Usage rate of the MSAC process
The MSAC system cannot be said to be fulfilling its criteria
if the system is not utilised. Between April 1998 and the
end of December 2004 ninety-one applications and
thirty-three references had been made to the Medicare
Benefits Branch, Department of Health and Ageing of the
Australian Government for evaluation by the MSAC. In
addition to assessments initiated by applications (applica-
tions), MSAC's terms of reference allow the Committee to
undertake reviews (references) as referred by the Minister
or the Department of Health and Ageing. The procedures
covered by these application and references are shown in
Tables 2a and 2b.
Although Tables 2a and 2b show a wide diversity of appli-
cations and references for new procedures requiring sub-
sidy via the establishment of new MBS Item Numbers, the
total number is low averaging only approximately nine-
teen per year. Compare this to the number of existing MBSAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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Table 2a: Application to the MSAC and Duration of Assessment
App. Description First MSAC 
Meeting
MSAC Meeting 
– Endorsed
Minister 
Sign Off
Duration 
in Months
MSAC 
Outcome
1001 Advanced breast biopsy instrumentation May'98 May'99 12 Negative
1002 Oto-acoustic emission audiometry May'98 Aug'99 15 Positive
1003 OctreoScan¨ scintigraphy for gastro-entero-
pancreatic neuroendocrine tumours
May'98 Aug'99 15 Positive
1004 Transmyocardial laser revascularization May'98 Aug'99 Sept'99 16 Negative
1005 Visual electrodiagnosis May'98 May'01 Jun'01 25 Partial
1006 Endoluminal grafting for abdominal aortic aneurysm May'98 May'99 12 Partial
1007 Saline infusion sonohysterography May'98 May'99 12 Positive
1008 Photodynamic therapy for skin and mucosal cancer May'98 May'99 12 Negative
1009 Sacral nerve stimulation for urinary incontinence May'98 Mar'00 22 Negative
1010 Intravascular extraction of chronically implanted 
permanent transvenous pacing leads
Sept'98 Aug'99 Sept'99 12 Positive
1011 Lung volume reduction surgery – for advanced 
emphysema
Sept'98 Feb'01 Apr'01 19 Negative
1012 Vertebral axial decompression therapy for chronic 
back pain
Feb'99 May'01 Jun'01 28 Negative
1013 Treatment of diseases of the inner ear using the 
Round Window Microcath System
Aug'99 - Ineligible
1014 TransUrethral Needle Ablation for benign prostatic 
hyperplasia
May'99 Nov'01/Mar'02 May'02 36 Interim
1015 Directional, vacuum-assisted breast biopsy May'98 Aug'99 Sept'99 16 Interim
1016 Samarium153-lexidronam for bone pain due to 
skeletal metastases
May'98 Aug'99 15 Positive
1017 Chelation therapy – for cardiovascular disease Nov'98 - Ineligible
1018–
1020
Hyperbaric oxygen treatment May'99 Feb'01 21 Partial
1022 Commercial-in-Confidence Application May'99 - Ineligible
1023 Placement of artificial bowel sphincters in the 
management of faecal incontinence
May'99 Nov'99 Nov'99 12 Negative
1024 Total ear reconstruction May'99 Mar'00 10 Positive
1025 Provision of Positron Emission Tomography (PET) 
services – deferred. See Reference 02
Aug'99 Aug'00 12 Ref 02
1026 Near patient cholesterol testing using the 
Cholestech LDX
Aug'99 Aug'01 Sept'01 25 Interim
1027 Provision of Positron Emission Tomography (PET) 
services – deferred. See Reference 02
Aug'99 - Ref 02
1028 Gamma knife surgery Nov'99 Nov'00 Aug'01 21 Negative
1029 Brachytherapy for the treatment of prostate cancer Nov'99 Nov'00 Feb'01 15 Interim
1030 Low intensity ultrasound treatment for the 
acceleration of bone fracture healing – 
Exogen\texttrademark bone growth stimulator
Feb'00 Nov'01 Feb'02 24 Negative
1031 Deep brain stimulation for symptoms of advanced 
Parkinson's disease
May'00 May'01 Jun'01 13 Interim
1032 Intravascular ultrasound May'00 Mar'02 May'02 24 Negative
1033 Autogenous cartilage implantation May'00 ? On hold
1034 Selective Internal Radiation Therapy for hepatic 
Metastases using SIR-Spheres®
May'00 Nov'01/Mar'02 Aug'02 27 Negative
1035 Genetic test for Fragile X syndrome May'00 Mar'02 Aug'02 27 Positive
1036 Percutaneous transluminal coronary rotational 
atherectomy for lesions of the coronary arteries
Aug'00 Sept'02 25 Partial
1037 Advanced breast biopsy instrumentation (Note 
earlier application 1001)
Aug'00 Aug'01 Sept'01 13 Positive
1038 Conformal radiotherapy Aug'00 Nov'01 Feb'02 18 Positive
1039 Photodynamic therapy with verteporfin for macular 
degeneration
Nov'00 Aug'01 Sept'01 10 Partial
1040 Anatomical biomodelling Nov'00 - Ineligible
1041 Intravascular Brachytherapy – Commercial-in-
Confidence application
May'01 Aug'02 Oct'02 17 Interim
1042 Cardiac resynchronisation therapy (CRT) May'01 Aug'05 55+ PositiveAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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1043 Thyrogen\texttrademark (thyrotropin alfa) as a 
diagnostic agent for well-differentiated thyroid 
cancer
May'01 Aug'02 Oct'02 17 Negative
1044 Ostase immunoassay for the mass measurement of 
serum bone alkaline phosphatase
May'01 May'03 Aug'03 27 Negative
1045 Intra-articular viscosupplementation for treatment 
of osteoarthritis of the knee
Aug'01 Mar'03 19 Negative
1046 Interstim for sacral nerve stimulation in patients 
with refractory urinary incontinence
Aug'01 Jun'02 11+ Negative
1047 Endoluminal Gastroplication for the treatment of 
Gastro-Oesophageal Reflux Disease GORD
Aug'01 Jun'02 10 Negative
1048 Intradiscal electrothermal anuloplasty for patients 
with chronic low back pain due to anular disruption 
of contained herniated discs
Aug'01 Nov'02 Dec'02 16 Negative
1049 M-VAX TM – a treatment for patients with 
advanced stage III melanoma
Nov'01 Aug'02 Oct'02 11 Negative
1050 Optical Biometry Nov'01 Mar'03/Aug'03 Jun'04 31 Positive
1051 Vacuum Assisted Closure (VAC) Therapy Nov'01 - Ineligible
1052 Radiofrequency ablation of liver tumours Nov'01 May'03 Aug'03 21 Partial
1053 Placement of artificial bowel sphincters in the 
management of faecal incontinence
Mar'02 May'03 ? 14+ Negative
1054 Hyperbaric Oxygen Therapy (Resubmission) Mar'02 May'03/Aug'03 Aug'04 29 Interim
1055 Hysteroscopic sterilisation by tubal cannulation and 
placement of intrafallopian implants
Mar'02 Nov'03 Mar'05 36 Negative
1056 LeukoScan® May'02 May'03 Aug'03 15 Partial
1057 M2A® capsule endoscopy – evaluation of obscure 
gastrointestinal bleeding in adult patients
Aug'02 Aug'03 Sept'03 16 Interim
1058 QuantiFERON-TB Gold Aug'04 - Withdraw
n
1059 Endo Venous Laser Treatment for Varicose Veins Mar'03 Nov'03 Aug'04 17 Negative
1060 Bone Mineral Densitometry – Reference 19 Mar'03 Nov'04 - Withdraw
n
1061 Implantation of Insertable Loop Recorder for 
Diagnosis of Recurrent Unexplained Syncope
Mar'03 Nov'03 8+ Positive
1062 A scan for Imaging Recurrence and/or metastases in 
patients with histologically demonstrated carcinoma 
of the colon or rectum
Mar'03 May'04 Aug'04 17 Negative
1063 Photodynamic Therapy for Verteporfin (Visudyne) 
for Subfoveal choroidal neovasculanisations 
(Commercial in Confidence)
Mar'03 Nov'03 Mar'05 24 Unchanged
1064 Three dimensional magnetic electroanatomical 
radiofrequency ablation for the treatment of cardiac 
arrhythmia's
Mar'03 - Ineligible
1065 Sentinel Node Biopsy for Breast Cancer Mar'03 Mar'05 Jul'05 28 Interim
1066 Drug (Sirolimus) Eluting Stents ("Commercial-in-
Confidence") – Refer to Reference 21
Mar'03 Aug'03 Sept'03 - Ref 21
1067 Genotypic resistance testing of antiretrovirals in HIV Aug'03 Aug'04 Mar'05 19 Negative
1068 Prostate specific antigen (PSA) test Mar'04 Mar'05 Jul'05 16 Unchanged
1069 Endoscopic ultrasound for the pre-operative staging 
of gastric and oesophageal neoplasms – Refer to 
Application 1072
Mar'04 21+ App 1072
1070 An innovative patent for tobacco smoking cessation Mar'04 - Ineligible
1071 Measurement of international normalised ratio 
(INR) in general practice
Mar'04 May'05 Jul'05 16 Negative
1072 Endoscopic ultrasound for staging pancreatic, 
gastric, oesophageal and hepato-biliary neoplasms
Mar'04 21+ Incomplete
1073 METVIX (Commercial-in-confidence) – referred to 
the PBAC
Mar'04 Withdraw
n
1074 Freelight Lambda and Freelight Kappa Mar'04 - Withdraw
n
1075 Endoscopic ultrasound for the diagnosis and pre-
operative staging of Hepato-biliary neoplasms – 
Refer to Application 1072
Mar'04 21+ Incomplete
1076 Transurethral microwave thermotherapy (TUMT) May'04 19+ Positive
1077 Sacral nerve stimulation for faecal incontinence May'04 May'05 Jul'05 14 Positive
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Item Numbers. The November 2004 edition of the Medi-
care Benefits Schedule runs for 696 pages with 190 pages
of listings for therapeutic procedures (with up to twenty
Item Numbers per page), another 56 pages for diagnostic
procedures and diagnostic imaging, and 25 pages of
pathology services.
Medical practitioners as a source of MSAC applications 
and 'Item Drift'
When the MSAC was established in 1998 it was assumed
that the majority of applications would originate from the
professional medical associations that represent the med-
ical practitioners since the Medicare Benefits Schedule
(MBS) is primarily a schedule of fees for the payment of
the medical practitioner. A summary of the sources of
MSAC application and references, divided into financial
Years (1st July to 30th June), is shown in Table 3. In the
June 2003 to July 2004 Financial Year, only one of the fif-
teen applications came from the medical profession. The
remainder were sponsored by industry.
Possibly, some early experiences with this new system
resulted in alerting the medical practitioners that an
MSAC application is a time consuming and risky process.
An MSAC application results in attention being focused
on the usage of the existing MBS Item Number to cover
the new procedure. If the MSAC application is unsuccess-
ful, the wording of the existing Item Number will more
than likely be modified specifically to exclude the new
procedure.
A further possible explanation for this low usage rate of
the MSAC process by medical practitioners is a practice
that may best be referred to as 'Item Drift'. This is the prac-
tice of an established procedure evolving into a new pro-
cedure over time with the medical practitioner's fee being
claimed under the existing MBS Item Number. This prac-
tice is somewhat facilitated by the often broad and vague
wording of the descriptors of the existing Item Numbers.
A clear example of this is the low number of laparoscopic
procedures listed on the MBS despite laparoscopic surgery
being common practice. The additional time and skills
required by the medical practitioner to perform a new
procedure can be covered by simply increasing the gap
payable by the patient (total fee charged minus amount
covered by the MBS Item Number).
Industry as a source of MSAC applications
Despite the original expectation that the majority of
MSAC applications would originate from professional
medical organisations, the source of applications has
quickly moved to the medical devices and equipment
industry as being the major, and virtually only, source of
applications. In 2004 all but one MSAC application came
from the medical devices and equipment industry, raising
the question as to why this industry is taking such a lead-
ing role in a process primarily designed to facilitate fees
for medical practitioners.
The answer lies with the nature of the new procedures. A
close examination reveals that without exception all new
MSAC applications cover procedures that include the use
of new technology, that is, capital equipment, consuma-
bles, disposables, prostheses or medical devices. The pay-
ment for capital equipment, consumables and
disposables is determined by a process referred to as The-
atre Banding that determines the payment of theatre costs.
The 'banding' of a procedure is directly linked to the MBS
1078 Multifocal multichannel objective perimetry 
(MMOP)
May'04 Aug'04 3+ Negative
1079 Peripheral arterial tonometry with ascending aortic 
waveform analysis using the SphygmoCor system
May'04 Mar'06 19+ Incomplete
1080 Radi pressure wire Aug'04 Nov'05 16+ Incomplete
1081 Uterine artery embolisation Aug'04 16+ Incomplete
1082 SIR-Spheres® for the treatment of non-resectable 
liver tumours
Aug'04 11+ Interim
1083 Intac Implants Aug'04 11+ Negative
1084 Uro Vysion Aug'04 Nov'05 16+ Incomplete
1085 Carbon labelled urea breath test Nov'04 13+ Incomplete
1087 B-Type Natriuretic Peptide – includes 1086 Aug'04 16+ Incomplete
1089 Brachytherapy for the treatment of prostate cancer Nov'04 May'05 Jul'05 8 Interim
1090 Artificial intervertebral disc replacement – 
previously Reference 29
Mar'04 Nov'05 14+ Incomplete
1091 Minimally Invasive Robotic Assisted Radical 
Prostatectomy
Mar'05 9+ Incomplete
1092 Deep brain stimulation for the symptoms of 
Parkinson's disease
Mar'05 9+ Incomplete
1093 Endovascular Neurointerventional Procedures Mar'05 9+ Incomplete
Source: MSAC Web Site: http://www7.health.gov.au/msac/ – Accessed 6th Jan'06 Correct as at end Dec'05
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Table 2b: References to the MSAC and Duration of Assessment
Ref No. Description First 
MSAC 
Meeting
MSAC 
Meeting – 
Endorsed
Minister 
Sign Off
Duration 
in Months
MSAC 
Outcome
1 Prostate cancer screening Unknown
2 Positron emission tomography (PET) Aug'99 Interim
3 Assisted reproductive technology (ART) Unknown
4 Nuchal translucency measurement in the first 
trimester of pregnancy for screening of 
trisomy 21 and other autosomal trisomies
Aug'99 Oct'02 38 Negative
5 Provision of pulmonary 
thromboendarectomy (PTE)
Aug'99 Feb'01 Mar'01 19 Positive
6a & 6b Intracytoplasmic sperm injection (ICSI) using 
ejaculated sperm
Nov'00 Mar'05 52+ Positive
7a Magnetic Resonance 
Cholangiopancreatography
Positive
7b Magnetic resonance imaging – (b) Staging of 
endometrial and cervical carcinoma
Nov'00 Nov'01 Feb'02 15 Positive
8 Intra-operative transoesophageal 
echocardiography
Nov'00 Jun'02 19 Interim
9a(i) Polymerase chain reaction (PCR) in the 
diagnosis and monitoring of chronic myeloid 
leukemia (CML)
Nov'00 Mar'03 Jun'04 43 Positive
9a (ii) Polymerase chain reaction (PCR) in the 
diagnosis and monitoring of acute 
promyelocytic leukemia (APL)
Nov'00 Mar'03 Aug'03 33 Positive
9a (iii) Polymerase chain reaction (PCR) testing in 
the diagnosis and monitoring of acut myeloid 
leukaemia (AML)
Nov'00 Aug'03 Sept'03 34 Positive
9a(iv) Polymerase chain reaction in the diagnosis 
and monitoring of patients with BCR-ABL 
gene rearrangement in acute lymphoid 
leukaemia
Nov'00 Mar'04 Jun'04 43 Positive
9b Antenatal Screening for Heritable 
Thrombophilia (Assessment Report – August 
2002)
Nov'00 Aug'02 Oct'02 23 Negative
10 part 2 (i) Positron Emission Tomography (PET) – 
additional indications
Nov'00 May'01 Jun'01 7 Positive
10 part 2 (ii) Positron Emission Tomography (PET) – 
additional indications
Nov'00 May'01 6+ Interim
11a Off-Pump Coronary Artery Bypass (OPCAB) 
with the aid of Tissue Stabiliser
Nov'00 Mar'02 May'02 18 Positive
11b Minimally Invasive Direct Coronary Artery 
Bypass (MIDCAB) with the aid of Tissue 
Stabiliser
Nov'00 Mar'02 May'02 18 Positive
12a Liquid based cytology for cervical screening Aug'01 Aug'02 Oct'02 14 Negative
12b Human papillomavirus testing in women with 
cytological prediction of low-grade 
abnormality
Aug'01 Aug'02 Oct'02 14 Negative
12c Computer-assisted image analysis for cervical 
screening
Aug'01 May'03 Aug'03 24 Negative
12d Human papillomavirus testing for cervical 
screening
Aug'01 May'03 Aug'03 24 Negative
12e The use of human papillomavirus (HPV) 
testing to monitor effectiveness of treatment 
of high-grade intraepithelial abnormalities of 
the cervix
Aug'01 Mar'04 31+ Positive
13 Multifocal Multichannel Objective Perimetry Nov'01 Nov'02 Dec'02 13 Negative
14 Laparascopic adjustable gastric banding for 
morbid obesity
Mar'02 Aug'03 Sept'03 18 Positive
15 Transanal Endoscopic Microsurgery May'02 Mar'03 10 Positive
16 Positron Emission Tomography (PET) Aug'02 Nov'03 Mar'05 31 Positive
17 Neonatal Hearing Screening Aug'02 Mar'04 Mar'05 31 Unknown
18 Faecal Occult Blood Test Aug'02 May'03 Partial
19 Bone Densitometry Aug'02 Nov'04 27+ WithdrawnAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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Item Number used by the medical practitioner. If the
medical practitioner uses an existing MBS Item Number
the new capital equipment, consumables or disposables is
not covered. Similarly, the payment for prostheses or
medical devices is covered by a listing on The Prostheses
List. One of the criteria for a listing on this schedule is a
relevant MBS Item Number. It can be difficult to explain
how an MBS Item Number that has been in existence for
over a decade can cover a procedure that includes prosthe-
ses new on the market in 2004. Up until 2004, the
requirement for the procedure used to implant the pros-
thesis or medical device to be covered by a relevant MBS
Item Number in order for the prosthesis or medical device
to qualify for reimbursement, has rarely been enforced.
However, with the rapidly growing volume and costs of
prostheses and medical devices, private health insurers are
now lobbying for this criterion to be enforced.
Time taken for processing MSAC applications and 
references
According to the original press statement announcing the
introduction of the MSAC, "patients will benefit earlier
from the most advanced procedures drawing on the best
scientific and medical evidence"[6]. The details of the
processing times for each application or reference is
shown in Tables 1a and 1b and summarised in Table 3.
The overall average processing time was approximately 18
months for applications and 22 months for references.
The steps involved in processing an application can be
briefly outlined as follows:
￿ Pre-lodgement meeting between Applicant and Health
Technology Section.
Table 3: Applications & References – Duration of Assessment
Applications References
Number Percentage Number Percentage
1 – 12 months 20 27% 5 15%
13 – 18 months 26 35% 11 32%
19 – 24 months 15 20% 7 21%
25 – 36 months 12 16% 7 21%
36 + months 1 1% 4 12%
T o t a l 7 41 0 0 % 3 41 0 0 %
Average (months) 17.8 22
Range (months) 3 – 55 6 – 52
20 Carotid Stenting Mar'03 Mar'05 Jul'05 28 Partial
21 Drug (Sirolimus) eluting Stents – Report not 
published – Subsumed by Ref. 30
Mar'03 Aug'03 Ref 30
22 Treatment of hyperhidrosis of the axillae Nov'03 Withdrawn
23 Injection of Botulinum Toxin for the 
treatment of spasticity following stroke
Withdrawn
24 Injection of Botulinum Toxin for the 
treatment of focal spasticity in adults
Withdrawn
25 Magnetic resonance cholangiopancreatograpy 
(MRCP)
Nov'03 Mar'05 Jul'05 20 Positive
26 Positron emission tomography (PET) for 
epilepsy
Nov'03 Nov'04 Mar'05 18 Positive
27 Vertebroplasty Mar'04 12 Interim
28 Laparoscopic removal of malignancies Mar'04 Withdrawn
29 Artificial intervertebral disc replacement – 
Application 1090
Mar'04 Nov'05 21+ App 1090
30 Drug eluting stents Mar'04 Nov'04 Mar'05 12 Noted
31 Endometrial ablation for chronic ractory 
menorrhagia
Mar'04 Mar'05 Jul'05 16 Unchanged
32 Implantable Cardiac Defibrillators for 
Chronic Heart Failure
Nov'04 13+ Incomplete
33 Treatment of cerebral aneurysms Nov'04 13+ Incomplete
Source: MSAC Web Site: http://www7.health.gov.au/msac/ – Accessed 6thJan'06
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￿ Application lodged with the Health Technology Section.
￿ Written information to Applicant that application has
been received and deemed eligible.
￿ Project Officer from the Health Technology Section allo-
cated.
￿ Chairperson of Advisory Panel selected from the MSAC
at next scheduled meeting.
￿ Formation of Advisory Panel – letters sent out to rele-
vant 'Craft Groups' for nominations.
￿ Evaluators appointed by Health Technology Section and
requested to draft a protocol.
￿ First meeting of the Advisory Panel and Evaluators –
refinement of draft protocol.
￿ Draft protocol sent out to Applicant for comments (14
days).
￿ Comments on draft protocol reviewed by Advisory
Panel Chairperson and other members of panel if neces-
sary.
￿ Evaluators evaluate application (three months).
￿ Evaluators draft Assessment Report presented to the
Advisory Panel.
￿ Advisory Panel review draft Assessment Report – Evalu-
ators incorporate changes.
￿ Reviewed draft Assessment Report sent out to Applicant
for comments (one month).
￿ Response to the Applicant's comments to the Advisory
Panel by Evaluators.
￿ Assessment Report (complete with recommendation by
the Advisory Panel) and Applicant's comments presented
to the next MSAC meeting.
￿ Recommendation of the MSAC sent to the Minister for
Health and Ageing.
￿ Recommendation ratified by the Minister for Health and
Ageing.
Note that it is only the Applicant and the Evaluators that
have any time limits imposed.
The role of the Advisory Panel is to assist in the assessment
of each application and provide expert input into the
assessment process as well as ensuring that the Evaluator's
assessment is clinically relevant. Although the Advisory
panel is central to the process, it is also a major cause of
delay owing to the time taken to form this panel. The for-
mation and organisation of the first meeting of this panel
can take in excess of six months. During this time the only
progress made by the application is the briefing of the
Evaluators and the resulting draft protocol from the Eval-
uators. For example, an application received in December
did not have the first meeting of the Advisory Panel until
the following August.
The processing times detailed in Tables 2a and 2b do not
take into account the time between the lodgement of the
application and the next MSAC meeting, a period of up to
three months. However, far more importantly, once a
decision has been ratified by the Minister, the application
has to be processed by another committee, most often the
Medicare Benefits Consultative Committee (MBCC) for
the wording of the MBS descriptor and the determination
of the fee for the service. This process is not commenced
until the Minister has approved the MSAC recommenda-
tion. As a consequence a period of two years between the
date of the lodgement of an application and the actual
listing of the new procedure on the MBS as a claimable
Table 4: Sources of Applications and References by Financial Year
Applications References Total
Time Period  Industry Individuals Professional 
Medical 
Organisations
References Total
Apr'98 – Jun'00 14 10 11 0 35
Jul'00 – Jun'01 10 0 1 10 21
J u l ' 0 1  –  J u n ' 0 2 6113 1 1
J u l ' 0 2  –  J u n ' 0 3 7026 1 5
Jul'03 – Jun'04 14 0 1 7 22
Source: MSAC Annual ReportsAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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Item Number is not uncommon. This is clearly illustrated
in Table 5 using a selection of the applications lodged for
the first time in the second half of 2004.
Recommendations and outcomes of applications and 
references to the MSAC
Table 6 summarises the known and ratified (by the Minis-
ter for Health and Ageing) outcomes of all MSAC applica-
tions and references submitted up to the end of December
2004. It is difficult to quote a percentage of positive rec-
ommendations since these are divided into positive, par-
tial positive and interim recommendations.
A positive recommendation is basically a recommenda-
tion for an MBS Item Number covering the total indica-
tion applied for by the sponsor of the original application.
A partial positive recommendation is a recommendation
for an Item Number covering only part of the original
indication applied for by the sponsor. An interim recom-
mendation is temporary funding and is approved when
the evidence is inconclusive but suggests that the proce-
dure could be at least as safe, more effective, and more
cost-effective than the existing comparable procedure. In
these circumstances, the MSAC usually recommends
interim funding for a period of three years to enable data
collection and further evaluation of the procedure. These
applications require a reapplication at the end of the three
years based on the additional evidence collected during
that time in order to maintain funding. For example,
applications 1029 and 1031 that received interim funding
in 2002 were re-submitted as applications 1089 and 1092.
Application 1089 has been granted an extension of
interim funding in order to allow time for the collection
of data.
Tables 7a, 7b, 7c and 7d give a summary of the published
findings from completed applications under the headings
of safety, effectiveness, cost-effectiveness, comment and
type. A simple qualitative analysis of these tables brings
up some interesting points.
As would be expected, any procedure that had a serious
safety concern was not recommended. Applications that
related to a procedure likely to be carried out on a small
number of patients were more likely to be given a positive
recommendation. Although often applications with posi-
tive or partial positive recommendations were based on
'solid' clinical evidence of effectiveness, this was not
always the case, especially in the case of interim funding.
Importantly, negative recommendations were in most
cases based on insufficient clinical evidence rather than
clinical evidence that clearly demonstrated a lack of clini-
cal effectiveness. It was rare for a recommendation, either
positive or negative, to be based on cost-effectiveness
since less than 10% of the literature search carried out by
the evaluators resulted in finding any acceptable papers
covering this criterion. Although, logically, this was to be
expected for applications with negative recommendations
due to insufficient clinical evidence, what was unexpected
was that it appeared to be equally true for those applica-
tions with positive recommendations. Diagnostic proce-
dures have a much higher total positive, partial positive or
interim recommendation rate compared to surgical or
therapeutic procedures. Therapeutical procedures were far
more likely to be ineligible compared to surgical or diag-
nostic procedures.
The number of negative recommendations based on
insufficient clinical evidence raises the important issue of
what level of clinical evidence is sufficient. With pharma-
ceuticals the gold standard is the Phase Three, double
blind, randomised, head-to-head clinical trial with statis-
tically significant outcomes. In 1995, the National Health
and Medical Research Council (NHMRC) prescribed a
schedule of levels of evidence by which the efficacy of
treatments could be assessed [7]. The 1999 revised version
of these levels of evidence is shown as Table 8.
However, the generation of evidence for a medical proce-
dure has to take into account a number of factors that do
not apply to a pharmaceutical. These include:
A new medical procedure often results from a process of
experimentation and variation of an existing established
procedure. Small incremental changes, over time, can
result in a new procedure substantially different from the
original procedure. However, it is unclear at what point
the procedure became a 'new' or different procedure.
Table 5: Processing times for Applications
Application Lodgement date MSAC meeting 
endorsed
Likely MBS listing date Processing time*
1087 Jul'04 Jun'06 May'07 2 years 10 months
1091 Dec'04 Mar'06/Jun'06 Nov'06/May'07 1 year 11 months/2 years 5 
months
1084 Jul'04 Nov'05 Nov'06 2 years 4 months
1080 May'04 Nov'05 Nov'06 2 years 6 months
* All these processing times assume that the Application is successful.Australia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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Clearly, a pharmaceutical company has a financial incen-
tive in investing in running a clinical trial on their prod-
uct. However, in the case of a procedure the identification
of who should carry out the clinical trial is far less clear.
Individual medical practitioners or their association do
not have the financial resources or the incentive.
In the case of a procedure that involves an implantable
prosthesis or an item of capital equipment, the manufac-
turer or distributor may have an incentive to carry out the
clinical trial. However, even if a medical device company
does go to the expense of running a clinical trial resulting
in a successful application to the MSAC, the resulting new
MBS Item Number cannot be restricted to the use of that
company's product. Any similar product from a competi-
tor can be used in the procedure. This reduces the possible
competitive advantage and thus incentive to carry out the
clinical trial.
The best timing of a clinical trial for a procedure can be
difficult to determine. If the trial is carried out too early
the outcome may not be optimal due to the lack of the
medical practitioner's experience or practice in perform-
ing the new procedure. Conversely, a delay in running the
clinical trial results in a reduction in the 'window of time'
on the return of the financial investment in the clinical
trial and the new technology.
In the case of a procedure that involves new technology,
there is the additional timing problem created by the on-
going development and refinement of the prosthesis or
capital equipment. Unlike a pharmaceutical that enters
the market as a finished product, prosthesis and capital
equipment continue to evolve once in the market based
on feedback from the medical practitioners and patients,
resulting in newer and better versions. A clinical trial
based on the first version will often generate less than
optimal results. However, a delay in carrying out the clin-
ical trial and the resulting delay in funding reduces the
financial viability of the product.
Clinical trials with statistically significant outcomes are
expensive to conduct. Unlike pharmaceuticals, where the
potential market is often measured in tens of millions of
dollars per annum, the market for prostheses and capital
equipment is far smaller. This limits the affordability of
clinical trial covering procedures.
Clearly, there are a number of challenges involved in the
generation of high level clinical evidence for medical pro-
cedures. At the same time, a public funding body such as
the Department of Health and Ageing of the Australian
Government cannot risk giving approval for a medical
procedure that has not been proven to be safe and effec-
tive.
Worldwide, there has been a rush of guidelines for the
evaluation of medical procedures with the more recent
efforts acknowledging the differences between pharma-
ceuticals, surgical procedures and diagnostic tests. Unfor-
tunately, the requirements of these guidelines are based
more on what should be, rather than what is, since there
would appear to have been less of a rush to generate the
evidence required by these guidelines. As a consequence,
the majority of negative recommendations from the
MSAC continue to be based on insufficient evidence.
Table 6: Outcomes of Applications and References
Outcome Applications References
Surgical Therapeutic Diagnostic Number Percentage Number Percentage
Positive 5 2 8 15 17% 17 39%
Interim 5 2 4 11 13% 4 9%
P a r t i a l 2327 8 % 2 5 %
Unchanged 0 1 1 2 2% 1 2%
Negative 10 9 7 26 30% 7 16%
S u b - T o t a l2 21 72 26 1 6 9 % 3 1 7 0 %
Ineligible 0 5 0 5 6% 0 0%
W i t h d r a w n 0224 5 % 5 1 1 %
U n k n o w n 1001 1 % 3 7 %
Other 2 0 3 5 6% 3 7%
Incomplete 5 0 7 12 14% 2 5%
TOTAL 30 24 34 88 100% 44 100%
Sourse: MSAC Web Site http://www7.health.gov.au/msac/index.htm accessed 6th Jan'06Australia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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Table 7a: Applications with Positive Recommendations
App. Description Safety Effectiveness Cost-
effectiveness
Comment Type
1002 Oto-acoustic 
emission 
audiometry
Only risk – false 
negative/positive 
results
Significant 
variation of results
Not undertaken The use of this technology appears 
to allow earlier identification of 
hearing impairment at less cost than 
alternative forms of testing.
Diagnostic
1003 OctreoScan¨ 
scintigraphy for 
gastro-entero-
pancreatic 
neuroendocrine 
tumours
Safe Sensitivity and 
specificity could 
not be determined
Not possible due 
to lack of data
GEP neuroendocrine tumours are 
relatively rare. Estimates of the 
incidence of carcinoid tumours vary 
between 7 and 13 cases per million 
population per year.
Diagnostic
1007 Saline infusion 
sonohysterograph
y
Safe Effective Cost-effective if 
resulting in 
prevention of 
other service
... as a second-line diagnostic 
procedure for abnormal uterine 
bleeding, when findings from 
transvaginal ultrasound are 
inconclusive.
Diagnostic
1010 Intravascular 
extraction of 
chronically 
implanted 
permanent 
transvenous pacing 
leads
Complications 
uncommon
Effective Insufficient data It is a much longer, more difficult and 
skilled procedure than extraction of 
leads not entrapped by fibrous 
tissue, which is performed by simple 
traction without the use of surgical 
tools. Currently, both procedures 
are remunerated at the same rate.
Surgical
1016 Samarium153-
lexidronam for 
bone pain due to 
skeletal metastases
As safe as 
alternative
Effective Not done but less 
costly than 
alternative
Carcinoma of the prostate or breast 
– second line treatment
Therapeutic 
radiopharma
ceutical
1021 Hepatitis C viral 
load testing
Safe Effective May be cost-
effective if good 
patient selection
.... only used for patients with 
confirmed hepatitis C (by ELISA or 
PCR test) who undertake antiviral 
therapy. Other restrictions apply.
Diagnostic
1024 Total ear 
reconstruction
Complication rate 
high but 
acceptable
Only one low level 
evidence trial
Insufficient data ... only a small number of procedures 
(15 to 20) are therefore expected to 
be performed each year.
Surgical
1035 Genetic test for 
Fragile X 
syndrome
No adverse events 
reported
Specificity was 
consistently high
$14,000 – $28,000 
per initial case 
found
Nucleic Acid Amplification (NAA) in 
those with specific clinical features of 
Fragile X (A) syndrome, including 
intellectual disabilities, and in first 
and second degree relatives of 
individuals with the Fragile X (A) 
mutation and Southern Blot where 
the results of NAA testing are 
inconclusive.
Diagnostic
1037* Advanced breast 
biopsy 
instrumentation 
(Note earlier 
application 1001)
Safety data differs 
widely
Low level data 
only
Insufficient 
evidence
... public funding should be 
supported for the diagnostic use of 
this procedure, as long as fees are 
such that health system costs do not 
exceed those of comparators.
Diagnostic – 
Biopsy
1038 Conformal 
radiotherapy
May result in 
reduced toxicity
Similar efficacy to 
comparator
More effective and 
less costly
.... based on the additional costs of 
MLC alone, CRT appears to be both 
more effective and less costly than 
standard radiotherapy (RT) in some 
patients groups.
Therapeutic 
– 
radiotherapy
1042 Cardiac 
resynchronisation 
therapy (CRT)
Appears to be safe As effective as 
pharmacotherapy
Patients who have moderate to 
severe chronic heart failure (NYHA 
class III or IV) despite optimised 
medical therapy, sinus rhythm, a left 
ventricular ejection fraction of less 
than or equal to 35% and a QRS 
duration greater than or equal to 
120ms.
SurgicalAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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Discussion and implications for health policy
Proposed timetable for the processing of applications to the MSAC
Presently there is no set timetable for the processing of
applications to the MSAC. Despite the fact that one of the
most crucial stages, the evaluation of the evidence, is given
a set time of three months, unexplained delays in other
stages of the process have resulted in applications taking
in excess of two years to generate a new MBS Item
Number. Table 9 shows a possible timetable for the
processing of applications covering the major steps in the
process. A set timetable would add a degree of certainty to
the process for the Applicant and would eliminate the
huge variation in the current processing time.
Appointment of Advisory Panels and the role of the Australian 
Medical Association (AMA)
The clinical and economic benefits of a positive MSAC
recommendation can be dramatically reduced if the rec-
ommendation is not arrived at in a timely fashion. The
MSAC process presently averages two years between the
acceptance of the application and the listing of the new
Item Numbers on the MBS. A major cause of this lengthy
delay is the amount of time spent forming the Advisory
Panel and agreeing on the dates of the first and subse-
quent meetings of this panel.
Currently, when a new application to the MSAC is
received by the Medicare Benefits Branch, one of the first
steps in the process is to write to the relevant medical asso-
ciation (Craft Group) and ask for nominations for posi-
tions on the Advisory Panel. This part of the process is
open-ended in terms of timing of the response from the
Craft Group and can take several months.
An example of the make up of expertise of the member-
ship of an Advisory Panel is that for Application 1089,
brachytherapy for the treatment of prostate cancer. This
panel included a nuclear medicine specialist (Chair and
MSAC member), two urologists, two radiation oncolo-
gists and, a consumer representative.
Discussions with the Australian Medical Association
(AMA) and Craft Groups aimed at formulating guidelines,
including timing, for the nomination process could facil-
itate a more rapid appointment of Advisory Panel mem-
bers and allow the first Advisory Panel meeting to be
convened within six weeks of the lodgement of an appli-
cation.
Interim funding
Currently, where the evidence is inconclusive but suggests
that the procedure could be at least as safe and possibly
more effective and cost-effective as the existing compara-
ble procedure, the MSAC may recommend interim fund-
ing for three years subject to the condition that additional
data be collected to allow further and longer term evalua-
tion of the procedure.
In its submission to the productivity commission inquiry
into impact of advances in medical technology on health
care expenditure in Australia the Faculty of Radiation
Oncology (RANZCR) stated that "the implementation of
new technology into Australia is affected by perceptions of
efficacy, international experience, and MSAC approval for
funding under the MBS. The introduction of new technol-
ogy is not necessarily consistent with MSAC requirements
in that the lag time to generate high-level evidence of ben-
efit is often not consistent with clinical imperatives to
introduce new technology. Furthermore, a chicken and
egg situation can develop where funding for equipment is
needed to generate evidence of effectiveness."[12]
1050 Optical Biometry Safe Accuracy is 
statistically 
superior to that of 
the commonly 
used AUS
May be less costly PCI may be a less costly 
measurement technique than AUS 
or IUS and that it offers comparable 
results to ultrasound techniques.
Diagnostic – 
Biometry
1061 Implantation of 
Insertable Loop 
Recorder for 
Diagnosis of 
Recurrent 
Unexplained 
Syncope
Unpublished as yet Unpublished as yet Unpublished as yet Patients with recurrent syncope who 
have had appropriate prior 
investigations.
Diagnostic
1076 Transurethral 
microwave 
thermotherapy 
(TUMT)
Unpublished as yet Unpublished as yet Unpublished as yet Patients with moderate to severe 
symptoms of benign prostatic 
hypertrophy.
Surgical
1077 Sacral nerve 
stimulation for 
faecal incontinence
Evidence of safety Some evidence of 
effectiveness
Some evidence of 
cost effectiveness
The total number of patients is small; 
there is some evidence of 
effectiveness and cost-effectiveness.
Surgical
Source: MSAC Reviews http://www7.health.gov.au/msac/msacapps.htm . Accessed 6th Jan'06
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Table 7b: Applications with Partial Positive Recommendations
App. Description Safety Effectiveness Cost-
effectiveness
Comment Type
1005 Visual 
electrodiagnosis
No significant risks 
identified
No rigorous 
evidence to 
support diagnostic 
accuracy
Could not be 
evaluated due to 
insufficient 
evidence
Funded – well-established tests: -
electroretinography; pattern 
electroretinography; dark 
adaptometry; electrooculography; 
visual evoked responses. Not 
funded – insufficient evidence: – 
focal electroretinography; 
multifocal electroretinography; 
multifocal visual evoked potential; 
scotopic threshold response; 
intensity response function.
Diagnostic
1006 Endoluminal 
grafting for 
abdominal aortic 
aneurysm
Long term could 
not be established
Have not been 
established
No rigorous 
Australian cost 
comparison
The current MBS items for 
abdominal aortic aneurysm be 
restricted to open aortic repair; 
but endoluminal repair continue to 
receive public funding under 
alternative arrangements.
Surgical
1018–
1020
Hyperbaric oxygen 
treatment
Some risk In some 
indications
Could be cost 
effective in some 
indications
Funded: – decompression illness, 
gas gangrene, air or gas embolism; 
diabetic wounds including diabetic 
gangrene and diabetic foot ulcers; 
necrotising soft tissue infections 
including necrotising fasciitis and 
Fournier's gangrene, and the 
prevention and treatment of 
osteoradionecrosis. Not funded – 
insufficient evidence: – thermal 
burns, non-diabetic wounds and 
decubitus (or pressure) ulcers, 
necrotizing arachnidism, 
actinomycosis, soft tissue 
radionecrosis, osteomyelitis, skin 
graft survival, multiple sclerosis and 
cerebral palsy, cardiovascular 
conditions including acute 
myocardial infarctions, 
cerebrovascular disease, and 
peripheral obstructive arterial 
disease (POAD), soft tissue injuries 
including acute ankle sprains and 
crush injuries, facial paralysis (Bell.s 
palsy), cluster and migraine 
headaches, Legg-Calve-Perthes 
disease (necrosis of the femoral 
head, especially prevalent in 
children), sudden deafness and 
acoustic trauma, Crohn.s disease, 
osteoporosis, cancer, carbon 
monoxide poisoning, cyanide 
poisoning, head trauma, cerebral 
oedema, acquired brain injury, 
cognitive impairment, senile 
dementia, glaucoma, 
keratoendotheliosis, HIV infection, 
anaemia from exceptional blood 
loss, insulin- dependent diabetes 
mellitus, facial neuritis, arthritis, 
spinal injuries and non-union of 
fractures.
TherapeuticAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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1036 Percutaneous 
transluminal 
coronary 
rotational 
atherectomy for 
lesions of the 
coronary arteries
Insufficient data Where 
conventional 
angioplasty and 
stenting cannot be 
undertaken 
successfully
Could not be 
determined
Funding: – revascularisation of 
complex and heavily calcified 
coronary artery lesions which 
cannot be treated by percutaneous 
transluminal coronary angioplasty 
(PTCA) alone or when previous 
PTCA attempts have not been 
successful; revascularisation of 
complex and heavily calcified 
coronary artery stenoses where 
coronary artery bypass graft 
(CABG) surgery is contra-
indicated. Not funded: – 
revascularisation of coronary 
artery stenoses which can be 
satisfactorily treated by PTCA 
alone, with or without stent 
placement; revascularisation of 
coronary artery in-stent 
restenoses as a result of prior 
coronary artery intravascular 
interventions (since no long-term 
data exist and short-term data are 
conflicting).
Surgical
1039 Photodynamic 
therapy with 
verteporfin for 
macular 
degeneration
Relatively high and 
precise number of 
adverse events
More effective 
than placebo in 
patients with 
classic choriodal 
neovascularisation
Modeling suggests 
a cost per vision 
year gained of 
$6,100-$35,400
Funded only for patients with 
predominantly classic (>50% 
classic) subfoveal choroidal 
neovascularisation secondary to 
MD, a small minority of MD cases. 
For this sub-group of MD patients, 
there is some evidence that the 
therapy may retard the rate of 
visual loss in the short term.
Therapeutic
1052 Radiofrequency 
ablation of liver 
tumours
No significant 
differences in 
complications
Statistically 
significant benefit 
for RFA over PEI 
in one RCT
More expensive Funded: – percutaneous treatment 
of non-resectable hepatocellular 
carcinoma not being considered 
for surgical resection. Not funded: 
– insufficient evidence – colorectal 
metastases (CLM); neuroendocrine 
liver metastases (NLM).
Therapeutic
1056 LeukoScan® Low probability of 
adverse events
Diagnostic 
accuracy not 
significantly 
different
Incremental cost is 
$24,056 and 
$26,348
LeukoScan is safe and as effective 
as current methods of WBC 
scanning, but is more costly. 
Additional funding is justified for 
patients who do not have access to 
ex-vivo WBC scanning.
Diagnostic 
– 
Radiopharm
aceutical
Source: MSAC Reviews http://www7.health.gov.au/msac/msacapps.htm. Accessed 6th Jan'06
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Table 7c: Applications with Interim Recommendations*
App. Description Safety Effectiveness Cost-
effectiveness
Comment Type
1014 TransUrethral 
Needle Ablation 
for benign 
prostatic 
hyperplasia
Relatively safe Relatively effective 
procedure for the 
short-term 
management
Additional clinical 
data is required
Limited role as an 
alternative 
treatment for 
symptomatic 
benign prostatic 
hyperplasia with 
the following 
restrictions: men 
with moderate to 
severe lower 
urinary tract 
symptoms that 
require specific 
treatment (ie 
those who would 
normally be 
recommended for 
TURP); not be 
medically suitable 
for TURP.
Surgical
1015 Directional, 
vacuum-assisted 
breast biopsy
Safe Seems to be more 
effective
Not undertaken Currently 
claimable under 
the MBS. The 
costs associated 
with the 
procedure should 
be investigated; 
and pending 
review of the 
costs, the 
procedure should 
receive interim 
funding at a higher 
remuneration than 
is currently 
available under 
existing items for 
nonpalpable breast 
lesions.
Diagnostic
1026 Near patient 
cholesterol testing 
using the 
Cholestech LDX
Safe Improved 
diagnostic 
accuracy over 
conventional
Problematic due 
to uncertainties
The unrestricted 
use of near patient 
cholesterol testing 
using the 
Cholestech LDX is 
not 
recommended. 
The restricted use 
of near patient 
cholesterol 
testing, as an 
alternative to 
laboratory testing 
of lipids, should be 
considered in 
settings or 
circumstances 
where there is 
adequate training, 
accreditation and 
quality assurance.
DiagnosticAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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1029 Brachytherapy for 
the treatment of 
prostate cancer
May offer less risk There has not 
been a successful 
randomised 
controlled trial
Slightly higher 
direct budgetary 
costs but may 
involve less 
indirect costs
Patients with 
prostate cancer at 
clinical stages T1, 
T2a or T2b, with 
Gleason Scores of 
less than or equal 
to 6, prostate 
specific antigen 
(PSA) of less than 
or equal to 10 ng/
ml, a gland volume 
less than 40 cc and 
with a life 
expectancy of 
more than 10 
years; and where 
the treatment is 
conducted at 
approved sites.
Surgical
1031 Deep brain 
stimulation for 
symptoms of 
advanced 
Parkinson's disease
limited evidence 
suggests
Some evidence – 
more long-term 
studies of 
improved 
methodological 
quality are needed.
Costs more than 
alternative over 5 
years.
For patients where 
their response to 
medical therapy is 
not sustained and 
is accompanied by 
unacceptable 
motor 
fluctuations; and 
subject to the 
patients' 
participation in an 
appropriate 
controlled trial to 
obtain information 
on adverse events, 
longer-term 
patient outcomes 
and costs in the 
Australian setting.
Surgical
1041 Intravascular 
Brachytherapy – 
Commercial-in-
Confidence 
application
Acceptable Based on level II 
and III-3 evidence.
Estimated to be 
approximately 
$31,500 per TLR 
prevented.
There is 
insufficient 
evidence on the 
safety and 
effectiveness of 
implanting 
radioactive stents 
to support public 
funding for this 
procedure. The 
short- and 
medium-term data 
on the safety and 
effectiveness of 
catheter based 
intravascular 
brachytherapy for 
the treatment of 
coronary artery 
restenosis is 
sufficient to 
warrant interim 
funding for this 
procedure.
Surgical
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10541 Hyperbaric 
Oxygen Therapy 
(Resubmission)
Adverse events 
self-limited and 
resolved after 
termination of 
therapy
RCT evidence was 
of low 
methodological 
quality, failing to 
meet relevant 
validity criteria.
Clinical evidence 
was inadequate to 
substantiate claims 
that (HBOT) was 
cost-effective.
The clinical 
evidence was 
inadequate to 
substantiate claims 
that hyperbaric 
oxygen therapy 
(HBOT) was cost-
effective in the 
treatment of 
refractory soft 
tissue radiation 
injuries or non-
diabetic refractory 
wounds. However, 
MSAC 
recommended 
that, as there are 
no effective 
alternative 
therapies and in 
view of the 
progress of local 
data collections 
and an 
international trial, 
funding for HBOT 
continue.
Therapeutic
1057 M2A® capsule 
endoscopy for the 
evaluation of 
obscure 
gastrointestinal 
bleeding in adult 
patients
Infrequent and 
mild adverse 
events.
Little available data 
on this 
technology's effect 
on patient 
management and 
long-term clinical 
outcomes.
Lower total health 
care costs overall.
Funding should be 
supported for this 
procedure for 
patients with 
confirmed 
recurrent obscure 
gastrointestinal 
bleeding following 
previous 
colonoscopy and 
endoscopy 
without identifying 
bleeding source.
Diagnostic
1065 Sentinel Node 
Biopsy for Breast 
Cancer
Appears to be safe Long term 
outcomes are 
uncertain
Based on cost 
minimisation, the 
cost to avoid 
lymphoedema. 
Therefore, the 
procedure 
appeared cost-
effective.
Long term 
outcomes are 
uncertain. Funding 
for sentinel node 
biopsy should be 
provided pending 
the outcome of 
trials already in 
progress and 
should be 
reviewed in five 
years.
Diagnostic – 
Biopsy
1082 SIR-Spheres® for 
the treatment of 
non-resectable 
liver tumours
Patients with 
hepatic metastases 
secondary to 
colorectal cancer 
which are not 
suitable for 
resection or 
ablation. Not 
funded for non-
resectable, non-
ablatable 
hepatocellular 
carcinoma.
Therapeutic
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RANZCR went on to say that 'the nature of equipment-
based developments and the process of obtaining suffi-
cient data for approval is a complex one, and there has
been at least one instance in the Faculty's field (brachy-
therapy for prostate cancer) in which MSAC provided an
interim approval. There have been challenges in collecting
data to gain ongoing approval of MBS funding, especially
when this is undertaken in an arm's-length manner from
the equipment manufacturers, along the lines of clinical
trial data collection protocols."
If interim funding in an expanded form, subject to the on-
going collection of data, is to be a solution to the 'insuffi-
cient evidence' problem, there are clearly a number of
issues that need to be resolved. Foremost of these issues
are the funding of the cost of the data collection, the dura-
tion of the data collection and, who will be responsible
for the collection of the data. A major drawback of an
interim funding system is the problems associated with
the discontinuation of funding should the data collected
show the procedure not to be cost-effective. Owing to the
fairly recent nature of the implementation of the MSAC
process only one application that was initially granted
interim funding has been reassessed. This application was
brachytherapy for the treatment of prostate cancer (Appli-
cation 1089) and it has been granted an extension of
interim funding in order to allow more time for data col-
lection.
A rare example of a government funded audit of a proce-
dure granted interim funding by the MSAC is the audit of
endoluminal repair of abdominal aortic aneurysms
(Application 1006). The 1999 MSAC report on this proce-
dure found that although it appeared to be effective in the
short-term, there was insufficient evidence relating to the
long-term safety and effectiveness. The Australian Audit of
Endoluminal Graft (ELG) Repair of Abdominal Aortic
Aneurysms (AAA) was established in 1999 to evaluate the
mid- to long-term safety and efficacy of the procedure in
the Australian setting. Results from the audit will help to
inform funding decisions made by the Australian Govern-
ment [14].
As at May 2005, this audit based on procedures carried out
between November 1999 and May 2001 is on-going with
a cost already measured in the hundreds of thousands of
dollars.
Unlike pharmaceuticals, the financial beneficiary from
the reimbursement of a new medical procedure can be dif-
ficult to identify. This raises the question of who should
pay for the production, collection and analysis of the evi-
dence. Table 4 shows that for the four year since July 2000,
86% of applications received by the MSAC have come
from industry. This is due to the fact that these new med-
ical procedures involve the use of new technology manu-
factured or distributed by medical device, medical
equipment or diagnostic companies and an MBS listing is
crucial to the commercial viability of these products.
Clearly, industry needs to be informed, and thus aware of
the minimal level of evidence required by the MSAC proc-
10892 Brachytherapy for 
the treatment of 
prostate cancer
Unchanged from 
1029
Unchanged from 
1029
Unchanged from 
1029
As a result of re-
assessment of 
further evidence – 
interim public 
funding should 
continue for 
patients with 
prostate cancer at 
clinical stages T1 
and T2 with 
Gleason Scores of 
less than or equal 
to 6, prostate 
specific antigen 
(PSA) of less than 
or equal to 10 ng/
ml, gland volume 
less than 40 cc and 
with life 
expectancy of 
more than 10 
years.
Surgical
1 Re-application for Application 1018–20
2 Re-application for 1029
* As a general rule all interim funding is subject to data collection and is for a period of three years.
Source: MSAC Reviews http://www7.health.gov.au/msac/msacapps.htm. Accessed 6th Jan'06
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Table 7d: Applications with Negative Recommendations
App. Description Safety Effectiveness Cost-effectiveness Type
1001 Advanced breast biopsy 
instrumentation
Safe Available evidence 
does not suggest
Not undertaken Diagnostic – biopsy
1004 Transmyocardial laser 
revascularization
Carries risk & adverse 
events
Studies do not 
demonstrated/
sustained effect not 
proven
Savings if effects 
sustained
Therapeutic
1008 Photodynamic therapy for skin and 
mucosal cancer
Safe Trials too small, 
unproven
Not available Therapeutic
1009 Sacral nerve stimulation for urinary 
incontinence
Relatively high adverse 
event rate
Uncertain long term Expensive Surgical
1011 Lung volume reduction surgery – 
for advanced emphysema
Differs widely Limited data – not 
possible to determine 
long term
Insufficient 
information
Surgical
1012 Vertebral axial decompression 
therapy for chronic back pain
Detailed evidence 
lacking
Some/insufficient No evidence based 
conclusion can be 
drawn
Therapeutic
1023 Placement of artificial bowel 
sphincters in the management of 
faecal incontinence
Could not be assessed 
due to insufficient data
Lack of rigorous 
studies – not 
demonstrated
Could not be assessed Surgical
1028 Gamma knife surgery Lack of data – 
unproven
Uncertain Lack of safety & 
effectiveness data
Surgical
1030 Low intensity ultrasound treatment 
for the acceleration of bone 
fracture healing – 
Exogen\texttrademark bone 
growth stimulator
Safe for adults Trial results 
contradictory
Unfavourable Therapeutic
1032 Intravascular ultrasound Relative safe overall Insufficient evidence Insufficient evidence Diagnostic
1034 Selective Internal Radiation 
Therapy for hepatic Metastases 
using SIR-Spheres®
Limited evidence Some but insufficient 
evidence
Not possible due to 
unreliable evidence
Therapeutic
1044 Ostase immunoassay for the mass 
measurement of serum bone 
alkaline phosphatase
No safety risk Insufficient evidence Not performed Diagnostic
1045 Intra-articular 
viscosupplementation for 
treatment of osteoarthritis of the 
knee
May be at least as safe 
as alternatives
Limited evidence – as 
effective as 
alternatives
Little valid information 
but more expensive
Therapeutic
1046 Interstim for sacral nerve 
stimulation in patients with 
refractory urinary incontinence
Adverse event 
incidence relatively 
high
Effective but unproven 
for longer than 12 
months
Not published Surgical
1047 Endoluminal Gastroplication for 
the Treatment of Gastro- 
Oesophageal Reflux Disease 
(GORD)
Limited evidence – 
more data required
May be effective – 
Limited good quality 
data
Insufficient data Surgical
1048 Intradiscal electrothermal 
anuloplasty for patients with 
chronic low back pain due to anular 
disruption of contained herniated 
discs
Low complications Based on low level 
evidence
Insufficient evidence Surgical
1049 M-VAX TM – a treatment for 
patients with advanced stage III 
melanoma
Unable to determine 
due to poorly 
reported data
Not possible to assess 
due to low level 
evidence
Insufficient data Therapeutic
1053 Placement of artificial bowel 
sphincters in the management of 
faecal incontinence
Number of safety 
issues
Misleading findings Not possible due to 
lack of clinical 
evidence
Surgical
1054 Hyperbaric Oxygen Therapy 
(Resubmission)
High rate adverse 
events
Studies flawed – 
uncertain benefits
Not possible Therapeutic
1055 Hysteroscopic sterilisation by tubal 
cannulation and placement of 
intrafallopian implants
Appears to be 
relatively safe – short 
term data
Appears to be 
relatively effective – 
short term data
No evidence Surgical
1059 Endo Venous Laser Treatment for 
Varicose Veins
Safe Insufficient evidence Insufficient evidence TherapeuticAustralia and New Zealand Health Policy 2006, 3:3 http://www.anzhealthpolicy.com/content/3/1/3
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ess. If industry is to take a more active financial role in the
generation of evidence it may also be justified in seeking
a greater role in the process. At this stage industry has no
representative on either the MSAC or any of the Advisory
Panels. With new procedures that result from the develop-
ment of substantial capital equipment rather than new
variations of existing procedures (experimentation), for
example robotically assisted minimally invasive surgery,
the collection of affordable and acceptable clinical data
should be possible.
Ongoing and large scale evaluation of the cost effectiveness and the 
incorporation of economic considerations into guidelines
In their 2001 paper, Eccles et al [15] explored the methods
of incorporating cost issues within clinical guidelines and
concluded that unlike other areas of guideline develop-
ment, there is little practical or theoretical experience to
direct the incorporation of cost issues within clinical
guidelines.
In 2005 Richardson [16] concluded that:
"The scale of present evaluation activities is inadequate. In an
industry absorbing 9 percent of the GDP – the country's largest
industry – there should be ongoing and large scale evaluation
and re-evaluation of the cost effectiveness of the services pro-
vided. Evaluation should be based upon a comparison with the
full spectrum of substitute services. A failure to do this almost
certainly ensures that there will be widespread and significant
allocative inefficiency in the level and mix of services."
Despite the fact that the MSAC was the first of its kind in
the world, the National Institute for Clinical Excellence
(NICE) has overtaken it in terms of expertise due to a far
greater allocation of resources. Presently the Health Tech-
nology Section that manages the evaluation process is
understaffed and as a consequence struggling to cope with
the workload. There is an urgent need for an injection of
staff qualified to deal with not only the day to day admin-
istration of the evaluation process but also the develop-
ment of methodology aimed at generating acceptable
clinical evidence upon which to base cost-effectiveness
evaluations. Methodology developed for these new proce-
dures could also be applied to existing procedures that
have raised some concern. A major policy issue that has
become clear as a result of the evaluation of new proce-
dures is that many of the existing 'gold standards' used as
comparators are anything but gold and are based on little
or no real evidence.
Table 8: NHMRC Levels of Evidence
Level Study design
I Evidence obtained from a systematic review of all relevant randomised controlled trials.
II Evidence obtained from at least one properly designed randomised controlled trial.
III-1 Evidence obtained from well-designed pseudo-randomised controlled trials (alternate allocation or some other method.
III-2 Evidence obtained from comparative studies (including systematic reviews of such studies) with concurrent controls and 
allocation not randomised, cohort studies, case-control studies, or interrupted time series with a control group.
III-3 Evidence obtained from comparative studies with historical control, two or more single-arm studies, or interrupted time 
series without a parallel control group.
IV Evidence obtained from case series, either post-test or pre-test/post-test.
Source: MSAC Reviews http://www7.health.gov.au/msac/msacapps.htm. Accessed 6th Jan'06
1062 A scan for Imaging Recurrence and/
or metastases in patients with 
histologically demonstrated 
carcinoma of the colon or rectum
Safe Insufficient evidence Insufficient evidence Diagnostic
1067 Genotypic resistance testing of 
antiretrovirals in HIV
Appears to be safe Insufficient evidence Insufficient evidence Diagnostic
1071 Measurement of international 
normalised ratio (INR) in general 
practice
No excessive safety 
concerns
Limited data Limited to direct 
costs – uncertainty of 
effectiveness
Diagnostic
1078 Multifocal multichannel objective 
perimetry (MMOP)
Safe Insufficient evidence Could not be 
determined
Diagnostic
1083 Intac Implants Evidence pertaining to 
this procedure is 
immature and small in 
volume.
Lack of published 
comparative clinical 
studies does not allow 
for any cost 
effectiveness analysis
Surgical
Source: MSAC Reviews http://www7.health.gov.au/msac/msacapps.htm. Accessed 6th Jan'06
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Conclusion
New medical procedures are often the result of a process
of experimentation rather than formally conducted
research. The medical procedures being evaluated by the
MSAC are, in the majority of cases, procedures that have
been carried out elsewhere in the word for some time.
Ironically this includes diagnostic tests using capital
equipment developed in Australian itself. This raises the
question as to exactly why there is such a low rate of pos-
itive recommendations from the MSAC. The answer may
lie with what is considered to be an acceptable level of evi-
dence and the fact that we have yet to develop a financially
viable formal process for the generation of this level of
evidence in Australia or elsewhere in the world.
The key characteristics of this clinical evidence are afford-
ability, timeliness, systematic collection, unbiased and,
not anecdotal.
When possible, interim funding of a new procedure can
ensure the systematic collection of evidence while allow-
ing the use of the new procedure. The answer to the time-
liness question lies in a combination of a greater use of
interim funding as well as the elimination of the unpro-
ductive time usage that exists in the current MSAC process.
Affordability and the question of who should pay for the
generation, collection and analysis of the clinical evidence
is perhaps the most difficult to answer especially in the
case where the new procedure is the result of a process of
experimentation with an old procedure. In cases where
new technology is used, industry may be able to play a
role here. However, this must be dependant on industry
having a greater role in the MSAC decision making proc-
ess.
Up to this point in time the use of economics and cost-
effect analysis has not been feasible due to a lack of accept-
able levels of clinical evidence. Currently, only the cost
side of the equation is possible in the vast majority of new
medical procedures with this often working against the
new procedure since virtually all new procedures involve
the use of expensive new technology.
Unless a cost-effective way is found to collect acceptable
levels of evidence proving the clinical effectiveness of
these new procedures, formal processes of evaluation such
as that used by the Australian MSAC since 1998 will con-
tinue to run a very high risk of committing Type II errors,
that is, denying access to medical procedures that are ben-
eficial and efficient rather than risk a Type I error,
approval of a non-beneficial procedure.
Abbreviations
MSAC – Medical Services Advisory Committee
MBS – Medicare Benefits Schedule
PBAC – Pharmaceutical Benefits Advisory Committee
MBCC – Medicare Benefits Consultative Committee
PBS – Pharmaceutical Benefits Scheme
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Table 9: Possible timetable for the application process
Week Process
Week 0 Application lodged with the Health Technology Section.
Week 1 Written information to Applicant that application has been received and deemed eligible.
Week 2 Project Officer from the Health Technology Section allocated.
Weeks 2 – 8 Formation of Advisory Panel – letters sent out to relevant 'Craft Groups' for nominations.
Weeks 2 – 8 Evaluators appointed by Health Technology Section and requested to draft a protocol.
Week 10 First meeting of the Advisory Panel and Evaluators – refinement of draft protocol.
Week 12 Draft protocol sent out to Applicant for comments.
Week 14 Comments on draft protocol reviewed by Chairperson of the Advisory Panel and other members of panel if 
necessary.
Weeks 15 – 28 Evaluators evaluate Application.
Week 29 Evaluators draft Assessment Report presented to the Advisory Panel.
Weeks 30 – 31 Any reviews of draft Assessment Report carried out by the Evaluators.
Weeks 31 – 35 Reviewed draft Assessment Report sent out to Applicant for comments.
Week 36 Response to the Applicants comments to the Advisory Panel by Evaluators.
Next scheduled MSAC Meeting Assessment Report (complete with recommendation by the Advisory Panel) and Applicant's comments 
presented to the MSAC meeting (held every three months).
2 weeks post Meeting. Recommendation of the MSAC sent to the Minister.
6 weeks post Meeting. Decision by Minister of Health and Ageing.Publish with BioMed Central    and   every 
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